Has Avni Amratia, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,771 in general payments to Avni Amratia, MD across 80 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Avni Amratia, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Avni Amratia, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Avni Amratia, MD

Rheumatology · Atlanta, GANPI 1104385079

Payments from drug & device makers

$1,771in general payments, 2019–2025

Across 80 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$338
Amgen$272
UCB, Inc.$259
Johnson & Johnson$176
Aurinia Pharma U.S., Inc.$153
AstraZeneca$134
plus $439 from 10 others

What the payments were for

Food & beverage$1,71497%
Education$573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	18	$338
Amgen	16	$272
UCB, Inc.	12	$259
Johnson & Johnson(2 entities)	7	$176
Aurinia Pharma U.S., Inc.	2	$153
AstraZeneca	6	$134
Novartis	4	$95
GSK	4	$93
Sanofi	2	$53
Organon	2	$37
Pfizer	2	$36
Invivyd Inc	1	$32
Radius Health, Inc.	1	$29
ANI Pharmaceuticals, Inc.	1	$27
Genentech USA, Inc.	1	$19
E.r. Squibb & Sons, L.L.C.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LUPKYNIS$127

How this compares

$1,771 in reported general payments places this provider in the 30th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia →

Medicare billing

Part B allowed, 2024

$7,552

Medicare patients

Services billed

125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MethotrexateMethotrexate Sodium	12	$262
Prednisone	15	$89

Paid to pharmacies, not to this prescriber.

Other rheumatology in Atlanta

Wambui MachuaAtlanta$1.8M
Arezou KhosroshahiAtlanta$1.5M
Sung LimAtlanta$1.3M
Gary MyersonAtlanta$1.3M
Paul SutejAtlanta$451K
William WilsonAtlanta$344K
Prateek GandigaAtlanta$214K
Suzana JohnAtlanta$208K
Athanasios TiliakosAtlanta$163K
Kimberley WilsonAtlanta$41K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →